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PD‑L1 expression evaluated 
by 22C3 antibody is a better 
prognostic marker than SP142/
SP263 antibodies in breast cancer 
patients after resection
Yoon Jin Cha1,2, Dooreh Kim3, Soong June Bae2,4, Sung Gwe Ahn2,4, Joon Jeong2,4, 
Hye Sun Lee5, Soyoung Jeon5, Tae‑Kyung Yoo3, Woo‑Chan Park3 & Chang Ik Yoon3*
Immune checkpoint inhibitors (ICI) have demonstrated efficacy in the treatment of solid 
cancers. However, there is no unified predictive biomarker available for ICIs. We aimed to 
compare the prognostic impact of using three PD‑L1 antibodies (SP142, SP263, and 22C3) for 
immunohistochemical (IHC) analysis. We retrospectively investigated tumor tissues derived from 316 
breast cancer cases, by constructing tissue microarrays and by performing IHC staining. The immune‑
cell expression rate (for SP142 and SP263) and combined proportional score (for 22C3) were evaluated, 
and survival outcomes were analyzed. Prediction models were developed, and values of Harrel’s 
c‑index and areas under curves were calculated to compare the discriminatory power. Negative PD‑L1 
expression based on the 22C3‑IHC assay was determined to be an independent prognostic marker 
for recurrence‑free survival (RFS, P = 0.0337) and distant metastasis‑free survival (DMFS, P = 0.0131). 
However, PD‑L1 expression based on SP142‑ and SP263‑IHC assays did not reveal a prognostic 
impact. Among the three antibodies, adding PD‑L1 expression data obtained via 22C3‑IHC assay to 
the null model led to a significant improvement in the discriminatory power of RFS and DMFS. We 
suggest that PD‑L1 expression based on the 22C3‑IHC assay is a superior prognostic marker than that 
based on SP142‑ and SP263‑IHC assays.
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PD-L1  Programmed death ligand 1
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RFS  Recurrence-free survival
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Immunotherapy targeting programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) has 
demonstrated remarkable efficacy in the treatment of several solid cancers including breast  cancer1–8. PD-1, a 
transmembrane protein, plays an important role in downregulating functions of the immune  system9. PD-L1 
can be expressed in both tumor and immune cells. PD-L1/PD-1 binding has been shown to induce immune 
tolerance in peripheral  tissues9,10, in which the PD-L1/PD-1 signaling pathway promotes tumor escape from 
immune  surveillance10,11. Currently, diagnostic factors used to predict survival outcomes include the expression 
profiles of the tumor micro-environment and PD-L1/co-inhibitory  proteins12,13. PD-L1 immunohistochemistry 
(IHC) is the only clinically approved method for predicting response to immune checkpoint inhibitor therapy. 
However, PD-L1 IHC testing is complex due to the availability of multiple IHC assays, each with its own reagents 
and other clinical  designs4,5,8, resulting in nonuniform clinical application of PD-L1 IHC.
This study aimed to perform a comprehensive, retrospective evaluation of PD-L1 expression based on IHC 
assays with three PD-L1 antibodies (SP142, SP263, and 22C3) in tumors of patients with breast cancer. Accord-
ingly, we investigated PD-L1 expression in tumor samples and compared survival outcomes predicted by using 
PD-L1 expression data obtained using each PD-L1 antibody.
Results
Patient characteristics based on PD‑L1 expression. A total of 316 breast cancer patients at Gangnam 
Severance Hospital were included in this study. The median patient age was 50 years (range 25–86 years). Clini-
cal characteristics were grouped and compared based on PD-L1 expression according to antibody-IHC assays, 
as shown in Table 1. Positive PD-L1 expression was associated with higher Ki67, estrogen receptor (ER) and 
progesterone receptor (PR) negativity, triple-negative breast cancer (TNBC) subtype, and higher histological 
grade (HG). Positive PD-L1 expression was related to lower American Joint Committee on Cancer (AJCC) stage 
for the SP142 group, but not for the SP263 or 22C3 groups. Positive PD-L1 expression was associated with the 
receipt of chemotherapy for the SP263 group. There was no statistical difference in age, lympho-vascular inva-
sion (LVI), and receipt of radiotherapy between the three groups.
Correlation of PD‑L1 assays with breast cancer tissue microarray (TMA) results. TMAs with 
tumor tissues derived from 316 patients were subjected to staining procedures for each antibody. The repre-
sentative case that was triple-positive for all three antibodies (Fig. 1a–d) presented with > 90% of stromal tumor-
infiltrating lymphocytes (TIL) infiltration as well as intratumoral TIL. The discordant case that was positive for 
22C3 and SP263 antibodies, but lacked SP142 expression (Fig. 1e–h), exhibited lesser extent of TIL infiltration 
than the triple-positive case. For IHC assays, 289/316 (91.5%) of the investigated TMA cores were subjected 
to staining procedures and their PD-L1 expression was studied using the 22C3 antibody, whereas the PD-L1 
expression of 301/316 (95.3%) and 299/316 (94.6%) of the TMA cores was studied using SP142 and SP263 
antibodies, respectively. The prevalence of positive PD-L1 expression differed according to each PD-L1 anti-
body. Based on the results obtained with the use of the 22C3 antibody, 19.7% of the patients with breast cancer 
harbored PD-L1-positive tumors [combined positive score (CPS) ≥ 1]. However, only 14.3% of the patients har-
bored PD-L1-positive tumors according to SP142 staining (≥ 1% IC), and PD-L1 IHC staining using SP263 led 
to the obtainment of a higher numbers of patients with PD-L1-positive tumors (38.5%) (Fig. 2a). Tumor tissues 
derived from 273 patients were subjected to staining procedures with all three PD-L1 antibodies, and the cor-
respondence among PD-L1 expression in the three groups has been depicted in Fig. 2b. Agreement between the 
findings obtained using the three antibodies was moderate (κ = 0.413, P < 0.001). There was moderate agreement 
between 22C3 and SP263 (κ = 0.424, P < 0.001), but 22C3 vs. SP142 (κ = 0.398, P < 0.001), and SP142 vs. SP263 
(κ = 0.361, P < 0.001) showed fair agreements.
Prognostic significance of PD‑L1 expression based on the antibodies. At a median follow-up 
time of 78.5 months (range, 0–325 months), 49 patients developed recurrence. Among them, 39 exhibited dis-
tant metastasis and 14 demonstrated loco-regional recurrence (four cases presented with distant metastasis and 
loco-regional recurrence simultaneously). There were 2, 9, and 10 recurrences in cases of discrepancy between 
22C3 and SP142, 22C3 and SP263, and SP142 and SP263, respectively. Only negative PD-L1 expression based on 
the 22C3-IHC assay was significantly associated with decreased recurrence-free survival (RFS) [Fig. 3a; hazard 
ratio (HR) 2.537, 95% confidence intervals (CI) 1.188–5.421, P = 0.0337] and distant metastasis-free survival 
(DMFS) (Fig. 4a; HR 2.867, 95% CI 1.247–6.589, P = 0.0131, log rank test). However, RFS and DMFS did not dif-
fer significantly between negative and positive PD-L1 expression levels based on SP142- and SP263-IHC assays 
(Figs. 3b,c, 4b,c).
In the univariate Cox proportional hazard model, age and positive PD-L1 expression based on the 22C3-IHC 
assays were found to be significant prognostic factors for RFS (Table 2, HR 0.207 95%, CI 0.050–0.855, P = 0.0295). 
However, PD-L1 expression based on SP142- or SP263-IHC assays was not a significant factor in RFS (Table 2). 
In the multivariate analysis, PD-L1 expression based on the 22C3-IHC assays was confirmed as a significant 
predictor for RFS (Table 2, HR 0.206, 95% CI 0.050–0.853, P = 0.0293).
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Table 1.  Comparison of patient and tumor characteristics, and PD-L1 status in patients with breast cancer. 
SD, standard deviation; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth 
factor receptor-2; TNBC, triple negative breast cancer; HG, histological grade; LVI, lympho-vascular invasion. 
a Percentages calculated without missing values.
22C3 SP142 SP263
Negative, n = 232 Positive, n = 57
P-value
Negative, n = 258 Positive, n = 43
P-value
Negative, n = 184 Positive, n = 115
P-valueN (%) N (%) N (%) N (%) N (%) N (%)
Age (year, mean ± SD) 50.3 ± 11.2 49.4 ± 11.2 0.575 50.6 ± 11.2 49.2 ± 12.8 0.445 50.9 ± 11.2 49.9 ± 11.6 0.441
Ki67 (%, mean ± SD) 20.9 ± 18.9 41.3 ± 21.9  < 0.001 23.5 ± 21.0 34.6 ± 20.1 0.002 19.9 ± 19.1 34.2 ± 21.6  < 0.001
ER  < 0.001 0.008  < 0.001
Positive 84 (36.2) 3 (5.3) 81 (31.4) 5 (11.6) 74 (40.2) 12 (10.4)
Negative 148 (63.8) 54 (94.7) 177 (68.6) 38 (88.4) 110 (59.8) 103 (89.6)
PR  < 0.001 0.003  < 0.001
Positive 73 (31.5) 2 (3.5) 72 (27.9) 3 (7.0) 66 (35.9) 9 (7.8)
Negative 159 (68.5) 55 (96.5) 186 (72.1) 40 (93.0) 118 (64.1) 106 (92.2)
HER2a 0.427 0.503 0.642
Positive 51 (22.0) 10 (17.5) 54 (20.9) 7 (16.3) 39 (21.2) 22 (19.1)
Negative 177 (76.3) 47 (82.5) 201 (77.9) 35 (81.4) 142 (77.2) 92 (80.0)
Missing 4 (1.7) 0 3 (1.2) 1 (2.3) 3 (1.6) 1 (0.9)
Subtype a  < 0.001 0.001  < 0.001
Luminal/HER2(-) 71 (30.6) 1 (1.8) 70 (27.1) 1 (2.3) 64 (34.8) 7 (6.1)
HER2 ( +) 49 (21.1) 10 (17.5) 52 (20.2) 7 (16.3) 37 (20.1) 22 (19.1)
TNBC 108 (46.6) 46 (80.7) 133 (51.6) 34 (79.1) 80 (43.5) 85 (73.9)
Missing 4 0 3 (1.2) 1 (2.3) 3 (1.6) 1 (0.9)
HGa  < 0.001  < 0.001  < 0.001
I, II 119 (51.3) 12 (21.1) 126 (48.8) 9 (20.9) 107 (58.2) 28 (24.3)
III 106 (45.7) 45 (78.9) 123 (47.7) 34 (79.1) 71 (38.6) 84 (73.0)
Missing 7 (3.0) 0 9 (3.5) 0 6 (3.3) 3 (2.6)
AJCC stage#, a 0.181 0.042 0.287
I 62 (26.7) 21 (36.8) 70 (27.1) 20 (46.5) 52 (28.3) 40 (34.8)
II 128 (55.2) 33 (57.9) 149 (57.8) 19 (44.2) 102 (55.4) 61 (53.0)
III 30 (12.9) 3 (5.3) 29 (11.2) 2 (4.7) 21 (11.4) 11 (9.6)
Missing 12 (5.2) 0 10 (3.9) 2 (4.7) 9 (4.9) 3 (2.6)
LVIa 0.194 0.575 0.157
Negative 164 (70.7) 47 (82.5) 41 (15.9) 5 (11.6) 33 (17.9) 13 (11.3)
Positive 43 (18.5) 7 (12.3) 191 (74.0) 31 (72.1) 134 (72.8) 87 ((75.7)
Missing 25 (10.8) 3 (5.3) 26 (10.1) 7 (16.3) 17 (9.2) 15 (13.0)
Chemotherapya 0.125 0.779 0.043
Done 191 (82.3) 52 (91.2) 216 (83.7) 37 (86.0) 147 (80.0) 103 (89.6)
Undone 39 (16.8) 5 (8.8) 40 (15.5) 6 (14.0) 35 (19.0) 12 (10.4)
Missing 2 (0.9) 0 2 (0.8) 0 2 (1.1) 0
Neoadjuvant chemo-
therapya 0.789 0.355 0.109
Done 4 (1.7) 0 5 (1.9) 0 4 (2.2) 0
Undone 226 (97.4) 57 (100) 251 (97.3) 43 (100) 178 (96.7) 115 (100)
Missing 2 (0.9) 0 2 (0.8) 0 2 (1.1) 0
Radiotherapya 0.104 0.945 0.317
Done 98 (42.2) 31 (54.4) 121 (46.9) 20 (46.5) 83 (45.1) 59 (51.3)
Undone 133 (57.3) 26 (45.6) 136 (52.7) 23 (53.5) 100 (54.3) 56 (48.7)
Missing 1 (0.4) 0 1 (0.4) 0 1 (0.5) 0
Endocrine therapy  < 0.001 0.017  < 0.001
Done 107 (46.1) 5 (8.8) 103 (39.9) 9 (20.9) 95 (51.6) 17 (14.8)
Undone 125 (53.9) 52 (91.2) 155 (60.1) 34 (79.1) 89 (48.4) 98 (85.2)
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In the univariate analyses of DMFS, only PD-L1 expression based on the 22C3-IHC assay was a significant 
factor of favorable DMFS (Supplementary Table 1; HR 0.122, 95% CI 0.017–0.888, P = 0.0378). Multivariate analy-
sis confirmed that PD-L1 expression based on the 22C3-IHC assay was significantly associated with favorable 
DMFS (Supplementary Table 1; HR 0.121, 95% CI 0.017–0.886, P = 0.0376).
Figure 1.  Positive and negative expression patterns of three PD-L1 antibodies. A representative case that 
showed triple-positive features for all three antibodies (a–d) exhibited > 90% of the stromal tumor-infiltrating 
lymphocytes (TIL) infiltration as well as intratumoral TIL. Discordant case which was positive for 22C3 and 
SP263 antibodies but lacked SP142 expression (e–h) presented with less TIL infiltration than that shown by the 
triple-positive case.
Figure 2.  Immunohistochemical staining patterns of PD-L1 based on the use of three PD-L1 antibodies: (a) 
57/289 patients (19.7%) presented with positive PD-L1-expressing tumors using 22C3; 43/301 patients (14.3%) 
presented with positive PD-L1-expressing tumors using SP142; 115/299 patients (38.5%) presented with positive 
PD-L1-expressing tumors using SP263. (b) Venn diagram illustrated for correspondence and Kappa value of 
comparison of PD-L1 staining using three PD-L1 antibodies.
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Evaluation of Cox proportional hazard model using Harrel’s c‑index, net reclassification index 
(NRI), integrated discrimination improvement (IDI), and time dependent areas under the 
curve (AUC). To quantify the improvement of predictive ability contributed by PD-L1 expression according 
to each antibody utilized, we calculated Harrel’s c-index, NRI, and IDI for the multivariate models. The addi-
tion of data on PD-L1 expression based on the 22C3-IHC assay to the null model significantly increased the 
c-index for both RFS (model 1 in Table 3; HR 0.626, 95% CI 0.536–0.689, P = 0.0001) and DMFS (model 1 in 
Supplementary Table 2; HR 0.633, 95% CI 0.574–0.692, P < 0.0001). Furthermore, the addition also improved the 
discriminatory power of RFS measured by considering NRI and IDI (model 1 in Table 3; P = 0.0008 and P = 0.04, 
respectively). Moreover, it also demonstrated superior discrimination of DMFS measured by considering NRI 
(model 1 in Supplementary Table 2, P < 0.0001) and IDI (model 1 in Supplementary Table 2, P = 0.044). However, 
addition of PD-L1 expression data based on SP142- or SP263-IHC assays did not substantially improve the dis-
criminatory power of RFS and DMFS (model 2 and 3 in Table 3 and Supplementary Table 2).
In the time-dependent AUC model for RFS, the addition of PD-L1 expression data based on each of the 
three antibodies utilized to the null model increased the discriminatory ability (Table 3). However, addition of 
PD-L1 expression data based on the 22C3-IHC assay to the null model yielded higher discriminatory value than 
that based on SP142- and SP263-IHC assays (Table 3, Fig. 5a,b). In the time-dependent AUC model for DMFS, 
addition of PD-L1 expression data based on the 22C3-IHC assay to the null model demonstrated superior dis-
criminatory power (Supplementary Table 2) than that based on SP142- or SP263-IHC assays (Supplementary 
Table 2 and Fig. 5c,d).
Prognostic impact of PD‑L1 expression in TNBC. Clinical characteristics were compared according 
to PD-L1 expression based on each PD-L1 antibody-IHC assay performed for the TNBC subtype, as shown in 
Supplementary Table 3. Positive PD-L1 expression using the SP263 antibody was associated with HG and higher 
Ki67, and negative PD-L1 expression using the SP142 antibody was related to lower AJCC stage. Otherwise, 
there was no statistical difference in the other clinicopathologic characteristics.
Survival outcomes based on the PD-L1 expression according to each antibody utilized were compared for 
the TNBC subtype. RFS differed significantly according to the PD-L1 expression in all antibody-IHC assays 
(Supplementary Fig. 1a; HR 3.462, 95% CIs 1.489–8.048, P = 0.0039; Supplementary Fig. 1b; HR 2.701, 95% 
CIs 1.026–7.108, P = 0.0442, Supplementary Fig. 1c; HR 2.371, 95% CIs 1.097–5.127, P = 0.0281, respectively). 
Additionally, decreased DMFS was observed in the negative 22C3- and SP263-IHC assays in the TNBC subtype 
(Supplementary Fig. 2a; HR 4.184, 95% CIs 1.710–10.24, P = 0.0017; Supplementary Fig. 2c; HR 2.746, 95% CIs 
1.188–6.350, P = 0.0181, respectively), but it was not observed in the SP142-IHC assay (Supplementary Fig. 2b; 
HR 2.611, 95% CIs 0.922–7.398, P = 0.0708).
Figure 3.  Kaplan–Meier survival curves of recurrence-free survival (RFS) in relation to PD-L1 expression 
based on PD-L1 antibody-IHC assays in patients with breast cancer. (a) Patients with negative PD-L1 expression 
based on the 22C3-IHC assay were associated with poor RFS (HR 2.537, 95% CI 1.188–5.421, P = 0.0337, log-
rank test). (b, c) PD-L1 expression with SP142- and SP263-IHC assays did not show significantly different RFS.
Figure 4.  Kaplan–Meier survival curves of distant metastasis-free survival (DMFS) in relation to PD-L1 
expression based on PD-L1 antibody-IHC assays in patients with breast cancer. (a) Patients with negative PD-L1 
expression based on the 22C3-IHC assay were associated with poor DMFS (HR 2.867, 95% CI 1.247–6.589, 
P = 0.0131, log-rank test). (b, c) DMFS did not significantly differ based on SP142- and SP263-IHC assay results.
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Univariate analysis of RFS in each PD-L1 antibody was performed using the Cox proportional hazard model. 
In the TNBC subtype, positive PD-L1 expression based on 22C3- and SP263-IHC assays was a significant prog-
nostic factor for RFS (Supplementary Table 4; 22C3, HR 0.095, 95% CI 0.013–0.700, P = 0.021; SP263, HR 0.406, 
95% CI 0.176–0.934, P = 0.0034, respectively). However, PD-L1 expression based on the SP142-IHC assay was 
not a significant factor in RFS (Supplementary Table 4; P = 0.078).
In the multivariate analyses of RFS, only positive PD-L1 expression based on the 22C3-IHC assay was a 
prognostic factor of decreased recurrence (Supplementary Table 4; HR 0.114, 95% CI 0.015–0.848, P = 0.034), 
and not SP263 (Supplementary Table 4; P = 0.511).
Discussion
In an era where immune checkpoint inhibitors are being utilized for TNBC, we investigated the prognostic impact 
of three different PD-L1 antibodies, for which coupled immune checkpoint inhibitors were available, namely 
PD-L1 (SP142)-atezolizumab, PD-L1 (22C3)-pembrolizumab, and PD-L1 (SP263)-durvalumab. To evaluate 
the prognostic discriminatory power of each antibody, we established prediction models including a null model 
that did not include PD-L1 expression data for model development. PD-L1 expression based on the 22C3-IHC 
Table 2.  Cox proportional hazard analysis for recurrence-free survival (RFS). HR, hazard ratio; CI, confidence 
interval; HG, histologic grade; LVI, lympho-vascular invasion; ER, estrogen receptor; PR, progesterone 
receptor; HER-2, human epidermal growth factor receptor-2.
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
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assay was consistently the most powerful prognostic factor. Furthermore, pre-existing prediction models showed 
improved discriminatory power when PD-L1 expression based on the 22C3-IHC assay was added as a parameter. 
In this study, we focused on the manner in which PD-L1 expression based on different antibody assays correlated 
with long-term survival outcome and clinicopathologic characteristics.
Comparative analyses of concordant and discordant rates for different PD-L1 antibodies have not been widely 
 reported14–16. PD-L1 has been studied as a prognostic factor in breast  cancer17, with positive prognostic results 
being consistently reported despite the use of different antibodies and scoring  methods18–20. Recently, the IMpas-
sion130 trial demonstrated improved outcome in advanced TNBC patients presenting with PD-L1-expressing 
tumors who were treated with the SP142 antibody and the immune checkpoint inhibitor  atezolizumab4. In 
addition to the IMpassion130 trial, the KEYNOTE-522 clinical trial demonstrated an improved pathological 
complete response rate among early TNBC patients with PD-L1 (22C3)-expressing tumors after neoadjuvant 
treatment combined with  pembrolizumab5.
PD-L1 IHC is usually performed after surgical resection, and an accurate PD-L1 IHC assay could be done 
in the substantial amount of tumor tissue due to the tumor heterogeneity. Kim et al., reported relatively good 
agreement between small biopsy samples and surgical specimens in the three commercial PD-L1 antibodies 
(concordance rates of 73%–96%, 65%–80%, and 72%–91% between 26, 20, and 46 paired samples in 22C3, SP142, 
and SP263 PD-L1 IHC assays, respectively)21. Additionally, several studies have published reliable agreement rates 
between paired small tumor samples and surgical  specimens22,23. In breast cancer, all three assays demonstrated 
good correlation for IC score and the concordance rate was the highest at a 1% cutoff  value16.
This study has several limitations. First, this was a retrospective study conducted by utilizing samples collected 
before the immune checkpoint inhibitor era; therefore, we could not assess the real effect of immune checkpoint 
inhibitor on PD-L1-positive patients, Furthermore, although PD-L1 expression based on the 22C3-IHC assay 
seemed to exert the strongest influence on prognostic power, the RFS and DFMS graphs also demonstrated 
separation for the two other antibodies. With a sufficiently large population size, PD-L1 expression based on the 
SP263-IHC assay, and especially that based on the SP142-IHC assay, may demonstrate a significant prognostic 
effect. Interestingly, positive PD-L1 expression based on the SP142-IHC assay exerted no effect on RFS and 
DMFS, whereas PD-L1 expression based on the 22C3-IHC assay was revealed to be an independent prognostic 
factor. These results might have been derived from the cohort composition, as the cohort was not only composed 
of patients with TNBC but comprised a mixture of cases with varied molecular subtypes. Particularly, PD-L1 
expression based on the SP142-IHC assay only evaluated %IC within the tumor area including the peri-tumoral 
stroma. As most TMA cores are composed of the intra-tumoral area, the peri-tumoral immune cell (IC) might 
have not been included. Moreover, TIL are heterogeneously distributed; thus, underestimation of TIL and subse-
quent underestimation of PD-L1 expression might have occurred. Conversely, PD-L1 expression evaluated using 
22C3 was determined using the CPS method, wherein the denominator equaled the total number of tumor cells, 
and the numerator equaled the number of cells that showed positive staining for PD-L1 expression using 22C3. 
Using this method, the positivity rate using 22C3 might have been largely differed compared to that observed 
using SP142. However, this aspect could not explain the improved prognostic outcome of patients whose tumor 
tissues stained positively for PD-L1 expression in assays using the 22C3 antibody, and higher AUC values in the 
survival model with PD-L1 expression based on the 22C3-IHC assay.
In conclusion, our findings may indicate that PD-L1 expression based on the 22C3-IHC assay is a more 
powerful discriminatory marker than that based on SP142- and SP263-IHC assays in breast cancer. Our findings 
warrant additional validation using large-scale studies.
Methods
Patients. This retrospective study was initiated by collecting tumor tissues from 316 patients who under-
went primary curative surgery for breast cancer between September 1999 and June 2015 at the Gangnam Sever-
ance Hospital in Seoul, Korea. All patients were treated according to standard protocols. The following data were 
recorded: age at surgery, tumor size, lymph node status, HG, status of ER, status of PR, status of the human epi-
dermal growth factor receptor-2 (HER2), LVI, Ki67 leveling index, status of PD-L1 according to each antibody, 
treatment modalities, and survival outcomes. Tumor HG was determined using the modified Scarff–Bloom–
Table 3.  Evaluation of multivariate Cox proportional hazard model using Harrel’s c-index, NRI, IDI, and 
time-dependent AUC for RFS. AUC, area under the curve; CI, confidence interval; HR, hazard ratio; IDI, 
integrated discrimination improvement; NRI, net reclassification index; RFS, recurrence-free survival. *Null 
model: including age. **Model 1: Null model + 22C3. ***Model 2: Null model + SP142. ****Model 3: Null 
model + SP263.
Null model Model 1 Model 2 Model 3
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Harrel’s c index 0.584 (0.531–0.637) 0.0019 0.626(0.536–0.689) 0.0001 0.587(0.526–0.648) 0.0050 0.612(0.541–0.683) 0.0019
NRI 1 0.112(0.001–0.201) 0.0008 0.055(− 0.007–0.140) 0.0879 0.079(− 0.055–0.230) 0.2517
IDI 1 0.014(0.002–0.036) 0.04 0.003(− 0.002–0.022) 0.3436 0.007(− 0.001–0.036) 0.1938
Time dependent 
AUC 0.587 (0.544–0.630) 0.0001 0.636(0.585–0.687)  < 0.0001 0.606(0.557–0.655)  < 0.0001 0.606(0.543–0.669) 0.0009
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Figure 5.  Comparison of improved discriminatory performance for each PD-L1 antibody using the time-
dependent AUC graphs of RFS and DMFS. (a) Among the three PD-L1 antibodies, 22C3-IHC staining showed 
a higher AUC value in RFS. (b) Via addition to the null model in RFS, the improved AUC value based on the 
22C3-IHC assay was observed to be superior among the three PD-L1 antibodies (AUC of 22C3 = 0.636, AUC of 
SP142 = 0.606, AUC of SP263 = 0.606). (c) Among the three PD-L1 antibodies, 22C3-IHC staining demonstrated 
a higher AUC value for DMFS. (d) Via addition to the null model in DMFS, the improved AUC value based on 
the 22C3-IHC assay was found to be superior among the three PD-L1 antibodies (AUC of 22C3 = 0.634, AUC of 
SP142 = 0.584, AUC of SP263 = 0.596).
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Richardson grading system. Anatomical tumor-node-metastasis (TNM) classification was based on the TNM 
staging system of the American Joint Committee on Cancer, 8th edition.
All procedures were performed in accordance with the 1964 Declaration of Helsinki and its later amendments 
or comparable ethical standards. The study protocol was approved by the institutional review board (IRB) of the 
Gangnam Severance Hospital (local IRB No. 3–2018-0067). The need for informed consent was waived under 
the approval of the IRB due to the retrospective design of the study.
TMA construction, IHC staining, and interpretation of results. On hematoxylin and eosin-stained 
slides of tumors, a representative area was selected, and the corresponding spot was marked on the surface of 
the paraffin-embedded block. Using a hollow needle, the selected area was punched out and the resulting 2-mm 
tissue core was placed in a 10 × 5 recipient block. Each separate tissue core was assigned a unique TMA location 
number that was linked to a database including other clinicopathologic data.
As per methods previously  described24, 3 µm-thick tissue sections were sliced and obtained from formalin-
fixed paraffin-embedded TMA blocks. After performing deparaffinization with xylene and rehydration with 
alcohol graded solutions, IHC was performed using the Ventana Discovery XT Automated Slide Stainer (Ventana 
Medical System, Tucson, AZ, USA). Cell Conditioning 1 buffer (citrate buffer, pH 6.0; Ventana Medical System) 
was used for antigen retrieval. The slices were incubated with the primary antibodies against estrogen receptor 
(ER; 1:150, clone 6F11; Novocastra Laboratories, Ltd., Newcastle upon Tyne, UK), progesterone receptor (PR; 
1:100; clone 16; Novocastra Laboratories Ltd.), HER2 (1:1500; polyclonal; DAKO, Glostrup, Denmark), PD-L1 
(prediluted; clone SP142; Ventana Medical System), PD-L1 (prediluted; clone SP263; Ventana Medical System), 
and PD-L1 (1:50; clone 22C3; DAKO). The appropriate positive and negative controls were included.
Molecular subtyping. Nuclear staining values ≥ 1% were considered indicative of ER and PR  positivity25. 
HER2 staining was interpreted based on the 2018 American Society of Clinical Oncology/College of American 
Pathologists  guidelines26. Only samples with strong and circumferential membranous HER2 immunoreactivity 
(3 +) were considered positive, whereas those with 0 and 1 + HER2 staining were considered negative. Cases with 
equivocal HER2 expression (2+) were further evaluated for HER-2 gene amplification via silver in situ hybridiza-
tion (SISH). Breast cancer subcategorization was based on the results of IHC staining for ER, PR, HER2, as well 
as the SISH results for HER2. The specimens were categorized as follows: (i) Luminal/HER2-negative (ER- and/
or PR-positive and HER2-negative); (ii) HER2-positive (HER2-positive regardless of the ER and PR statuses); 
(iii) TNBC (ER-, PR-, and HER2-negative).
Interpretation of PD‑L1 immunohistochemistry results. For evaluating PD-L1 expression based on 
the 22C3-IHC assay, the CPS was calculated by dividing the number of stained cells expressing PD-L1 (tumor 
cells, lymphocytes, and macrophages) with the total number of viable tumor cells, and by multiplying the quo-
tient by 100. CPS ≥ 1 was considered as positive.
For PD-L1 expression based on the SP142-IHC assay, the intensity of tumor-infiltrating IC staining was exam-
ined. Immune cells present in the intra-tumoral and contiguous peri-tumoral stroma, including lymphocytes, 
macrophages, dendritic cells, and granulocytes, were evaluated. The % IC was determined as the proportion of 
tumor area exhibiting PD-L1 staining of any intensity. For deducing PD-L1 expression based on the SP263 IHC 
assay, staining of immune cells at any intensity was considered positive staining, and the total percentage of signal 
intensity was visually estimated to generate data on the PD-L1 expression level.
Representative images are shown in Fig. 1.
Statistical analysis. Recurrence-free survival (RFS) was defined as the period between the primary surgery 
and any case of recurrence (loco-regional and/or distant metastasis) of breast cancer, death occurring due to any 
cause, or event of the last follow-up. DMFS was defined as the period between the primary curative surgery 
and diagnosis of breast cancer-derived distant metastasis, death occurring due to any cause, or event of the last 
follow-up. The data of patients who did not exhibit relevant events were censored at the completion of follow-up.
Clinical characteristics were compared between PD-L1-negative and -positive groups assessed using each anti-
body. Continuous variables between the two groups were compared using the Student’s t-test or the Mann–Whit-
ney test. Categorical variables were compared using the Chi-square test or Fisher’s exact test. Survival curves were 
generated using the Kaplan–Meier method and compared between the two groups using the log-rank test. Cox 
proportional hazard models were used to identify factors associated with survival outcome (RFS and DMFS). We 
applied the backward likelihood method (specifies the significance level for entering effects = 0.10 and removing 
effects = 0.05) in the Cox proportional hazard models.
Time-dependent receiver operating characteristic curves were generated to ascertain the identity of the PD-L1 
antibody that presented with the most considerable contribution to the prognostic value. Furthermore, to inves-
tigate the additional prognostic power of PD-L1 expression based on the IHC assays performed using the three 













Scientific Reports |        (2021) 11:19555  | https://doi.org/10.1038/s41598-021-97250-2
www.nature.com/scientificreports/
the concordance for time-to-event data, in which increasing values between 0.5 and 1.0 indicated improved 
prediction. For model comparison, the bootstrapping method was used with resampling 1,000 times. We also 
assessed the NRI and IDI to evaluate the improvement in discriminatory ability contributed by PD-L1 expression 
using each of the three antibodies when data were added to the survival  model28. Significant improvement was 
recognized in the prediction model when NRI > 0 and IDI > 0.
Statistical analysis was performed using the IBM SPSS Statistics version 24 software (IBM Corp., Armonk, 
NY, USA). The threshold for statistical significance was set at P < 0.05, with a 95% confidence interval (CI) not 
including 1.
Consent for publication. All authors have provided consent for publication.
Ethics approval and consent to participate. All procedures performed in studies involving human 
participants were in accordance with the ethical standards of the institutional and/or national research com-
mittee and the 1964 Helsinki Declaration. The protocol was approved by the institutional review board (local 
IRB No. 3–2018-0067) of Gangnam Severance Hospital. The need for informed consent was waived under the 
approval of the IRB due to the retrospective design.
Data availability
The datasets generated and analyzed during the present study will be available from the corresponding author 
upon request.
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